Clinical Trials Browser

Ovarian Neoplasms

Colorectal Neoplasms

Colorectal Neoplasms

Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma

Colorectal Neoplasms

Ovarian Neoplasms

Carcinoma, Hepatocellular

Lung Diseases, Interstitial

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

Rectal Neoplasms

Carcinoma, Hepatocellular

Glioblastoma, Glioma

Colorectal Neoplasms

Advanced Microsatellite Stable Colorectal Cancer

Carcinoma, Hepatocellular

Colorectal Neoplasms

Stomach Neoplasms

Brain Neoplasms

Uterine Cervical Neoplasms

Carcinoma, Hepatocellular

Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

Colorectal Neoplasms

Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

Colorectal Neoplasms

Diabetes Mellitus, Insulin-Dependent, 12, Adenocarcinoma of Lung

Carcinoma, Hepatocellular

Colorectal Neoplasms

Colorectal Neoplasms

Rectal Neoplasms Malignant

Colorectal Neoplasms

Ovarian Neoplasms

Medulloblastoma

Colorectal Neoplasms

Colorectal Neoplasms

Colorectal Neoplasms

Platinum-resistant Recurrent Ovarian Cancer (PROC)

Carcinoma, Hepatocellular

Carcinoma, Hepatocellular

Appendiceal Neoplasms, Colorectal Neoplasms

Colorectal Neoplasms

Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Colonic Neoplasms

Colorectal Neoplasms

Carcinoma, Hepatocellular, Liver Neoplasms, Neoplasm Metastasis

Breast Cancer With Brain Metastasis

Disease, Colorectal Neoplasms

Ovarian Neoplasms

Clinical Trials

A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)

Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable Metastatic Colorectal Cancer

COLIBRI-GI

Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy

A Clinical Study of Liposomal Irinotecan for Second-Line Therapy in Metastatic Colorectal Cancer

RAINFOL™-07

Efficacy and Safety of Low-dose Bevacizumab Plus Adebrelimab Combined With Transarterial Chemoembolization Followed by Hepatic Arterial Infusion Chemotherapy (TACE-HAIC) as First-line Treatment for Unresectable Hepatocellular Carcinoma: A Single-arm Phase 2 Trial

Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease

Allogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced Solid Tumors

CRITⅡ

Low-Dose Bevacizumab and Atezolizumab Combined With TACE-HAIC in Unresectable Hepatocellular Carcinoma

Sitagliptin in Recurrent/Progressive Grade 4 Glioma

BEST

Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer

Sequential FOLFOX-HAIC-TACE Plus Sintilimab-Bevacizumab Neoadjuvant Therapy Versus Direct Resection in Resectable High-Risk Recurrence Hepatocellular Carcinoma

A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer

Efficacy of Sintilimab Combined With Bevacizumab and XELOX/SOX in Initially Unresectable AFP-positive Gastric/Gastroesophageal Junction Adenocarcinoma

A Phase II Clinical Study of Utidelone and Bevacizumab With or Without Etoposide in Patients With Brain Metastases From Malignant Solid Tumors

JSKN033 Combination Therapy in Subjects With Advanced Cervical Cancer

MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)

SYS6090 Combination Therapy in Advanced Lung Cancer

A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer

QLS5132 Combination Therapy in Advanced Solid Tumors

ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer

PHOENIX

A Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma

A Clinical Study on the Treatment of Metastatic Colorectal Cancer at the Second-line or Beyond.

LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation

CAPOX and Bevacizumab With or Without Primary Tumor Radiotherapy and Iparomlimab and Tuvonralimab as First-line Treatment for RAS-Mutant/MSS Metastatic Rectal Cancer

ROMANCE - GOIM

To Evaluate the Efficacy and Safety of JPI-547 in Combination With Bevacizumab as Maintenance Therapy in Relapsed Ovarian Cancer

IBI363 Plus Bevacizumab With or Without Nab-Paclitaxel for Second-Line Treatment of Advanced Gastric Cancer

Clinical Study on the Use of Huaier Granules for the Treatment of Proteinuria Related to Bevacizumab and Anlotinib in Lung Cancer Patients

PNOC044

ARIEL-ENGIC

Gossypol Acetate + FOLFIRI + Bev in mCRC With TP53-Mutant and LRPPRC Positive

A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation

Prospective, Multicenter, Single-Arm, Phase Ⅱ Clinical Study on the Efficacy and Safety of Sacituzumab Tirumotecan Combined With Bevacizumab in Platinum-Resistant Recurrent Ovarian Cancer

Transarterial Chemoembolization With Low-Dose Bevacizumab Plus Atezolizumab as First-Line Treatment for Unresectable Hepatocellular Carcinoma

Radiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic Hepatocellular Carcinoma

Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial

Trifluridine/Tipiracil Plus Fruquintinib vs. Trifluridine/Tipiracil Plus Bevacizumab in Refractory Metastatic Colorectal Cancer: A Randomized, Controlled, Open-Label, Non-Inferiority Trial

Sac-TMT Plus Bevacizumab as Second-Line Treatment for Advanced Non-Squamous Non-Small Cell Lung Cancer

HOFIBREN

REFISH

Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer

A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic Therapy

THUMB

SMARTi-RC01

Etoposide Capsules Combined With Bevacizumab and Iparomlimab and Tuvonralimab in the Treatment of Platinum Resistant or Platinum Refractory Ovarian Cancer